Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Editas Medicine, Inc.EDIT · Entity 5502 | EVP, CBO AND CTO | December 05, 2023 | December 07, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Editas Medicine, Inc.
Report date December 05, 2023 · Filed December 07, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 74,791 |
Reported balance
After 2023-12-05 transaction · row 1
1 source rowRow 1 · 2023-12-05 · Sale · Disposed 103 · Balance 74,791 F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. F2: This transaction was executed in multiple trades at prices ranging from $10.6149 to $10.9000. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. |
Filing footnotes · ownership attribution and instrument terms
F1: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2023. The sale does not represent a discretionary trade by the Reporting Person.
F2: This transaction was executed in multiple trades at prices ranging from $10.6149 to $10.9000. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 05, 2023 Filed Dec 7, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 103 | $10.90 | $1,122.41 |
DisclosureSEC source: 0001650664-23-000029 · wk-form4_1701984627.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,791 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $10.6149 to $10.9000. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| November 14, 2023 Filed Nov 16, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 695 | $8.21 | $5,705.67 |
DisclosureSEC source: 0001650664-23-000022 · wk-form4_1700170220.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 74,894 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 07, 2023 Filed Nov 9, 2023 16:31 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 139 | $8.40 | $1,167.60 |
DisclosureSEC source: 0001650664-23-000019 · wk-form4_1699565469.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,589 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 06, 2023 Filed Sep 7, 2023 16:59 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 103 | $8.82 | $908.46 |
DisclosureSEC source: 0001650664-23-000002 · wk-form4_1694120355.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,728 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 11, 2023 Filed Aug 15, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 702 | $8.59 | $6,032.64 |
DisclosureSEC source: 0001415889-23-012264 · form4-08152023_040803.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 75,831 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 08, 2023 Filed Aug 10, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 141 | $8.39 | $1,182.99 |
DisclosureSEC source: 0001415889-23-012049 · form4-08102023_040848.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,533 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| June 05, 2023 Filed Jun 7, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 105 | $9.50 | $997.82 |
DisclosureSEC source: 0001415889-23-009368 · form4-06072023_040602.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,674 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on June 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.4618 to $9.5034. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 11, 2023 Filed May 15, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 668 | $9.87 | $6,594.50 |
DisclosureSEC source: 0001415889-23-007989 · form4-05152023_040501.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 76,779 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 09, 2023 Filed May 11, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 135 | $9.51 | $1,283.85 |
DisclosureSEC source: 0001415889-23-007816 · form4-05112023_040501.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 77,447 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 6, 2023. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $9.5100 to $9.5150.The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 03, 2023 Filed Mar 6, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 101 | $8.89 | $897.89 |
DisclosureSEC source: 0001415889-23-004312 · form4-03062023_040302.xml · nonDerivative · entry 2 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,582 F2 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 50,000 | $0.00 Strike: $8.72 | $0.00 |
DisclosureSEC source: 0001415889-23-004312 · form4-03062023_040302.xml · derivative · entry 3 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2033-03-01 F3 · derivative.exercise_date: This option was granted on March 2, 2023 and is scheduled to vest over four years in equal monthly installments beginning on April 2, 2023 through March 2, 2027. Read SEC document |
| March 02, 2023 Filed Mar 6, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 16,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-004312 · form4-03062023_040302.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,683 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on March 2, 2024 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through March 2, 2027. Read SEC document |
| February 13, 2023 Filed Feb 15, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 3,307 | $9.67 | $31,963.15 |
DisclosureSEC source: 0001415889-23-002602 · form4-02152023_040201.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,983 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 10, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 346 | $11.10 | $3,840.60 |
DisclosureSEC source: 0001415889-23-002218 · form4-02092023_040202.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CBO AND CTO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,290 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2023. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| December 05, 2022 Filed Dec 6, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 102 | $10.23 | $1,043.46 |
DisclosureSEC source: 0001415889-22-012131 · form4-12062022_041201.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,636 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on December 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| November 08, 2022 Filed Nov 9, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 289 | $11.02 | $3,184.78 |
DisclosureSEC source: 0001415889-22-011242 · form4-11092022_041141.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,738 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| September 06, 2022 Filed Sep 8, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 101 | $15.01 | $1,516.01 |
DisclosureSEC source: 0001415889-22-009448 · form4-09082022_040901.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,027 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on September 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 09, 2022 Filed Aug 10, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 293 | $18.60 | $5,449.39 |
DisclosureSEC source: 0001415889-22-008463 · form4-08102022_040801.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,128 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2022. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $18.0525 to $18.61. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 03, 2022 Filed Jun 6, 2022 16:46 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,123 | $11.54 | $12,955.94 |
DisclosureSEC source: 0001415889-22-006162 · form4-06062022_010614.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,421 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units and in performance stock units on June 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| May 09, 2022 Filed May 11, 2022 16:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 297 | $13.11 | $3,894.50 |
DisclosureSEC source: 0001415889-22-004837 · form4-05112022_040501.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,544 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on May 6, 2022. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $12.8768 to $13.12. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request, to the SEC staff, the Issuer or a security holder of the Issuer, full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 01, 2022 Filed Apr 4, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 1,258 | $19.64 | $24,707.37 |
DisclosureSEC source: 0001415889-22-003709 · form4-04042022_040401.xml · nonDerivative · entry 2 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 66,841 F2 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 31, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| March 03, 2022 Filed Mar 7, 2022 16:15 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 403 | $17.33 | $6,983.06 |
DisclosureSEC source: 0001415889-22-002656 · form4-03072022_040308.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,386 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on March 2, 2022. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:22 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantStock Option (right to buy) · Derivative | 110,732 | $0.00 Strike: $17.29 | $0.00 |
DisclosureSEC source: 0001415889-22-001225 · form4-02112022_010246.xml · derivative · entry 2 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 110,732 Underlying: Common Stock · 110,732 shares Expires 2032-02-09 F2 · derivative.exercise_date: This option was granted on February 10, 2022 and is scheduled to vest over four years in equal monthly installments beginning on March 10, 2022 through February 10, 2026. Read SEC document |
| February 10, 2022 Filed Feb 11, 2022 16:22 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 37,593 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-22-001225 · form4-02112022_010246.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,789 F1 · security: The common stock received by the Reporting Person was in connection with the grant of a restricted stock unit award to the Reporting Person, for no consideration, and which is scheduled to vest over four years with 25% of the units vesting on February 10, 2023 and the remaining 75% of the units scheduled to vest in equal quarterly installments thereafter through February 10, 2026. Read SEC document |
| February 08, 2022 Filed Feb 10, 2022 16:36 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 302 | $17.63 | $5,323.08 |
DisclosureSEC source: 0001415889-22-001195 · form4-02102022_010215.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,196 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on February 6, 2022. The sale does not represent a discretionary trade by the Reporting Person. F2 · price: This transaction was executed in multiple trades at prices ranging from $17.61 to $17.82. The price reported above reflects the weighted average purchase price. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 22, 2021 Filed Dec 23, 2021 16:11 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | GrantCommon Stock | 3,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-21-011227 · edgar.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,498 F1 · kind: Reflects the acquisition, upon the achievement of a specified research and development milestone, of a portion of a performance-based restricted stock unit award originally granted on June 2, 2021. The shares subject to the restricted stock unit award remain subject to time-based vesting conditions and will vest on June 2, 2022, subject to continued service. Read SEC document |
| November 09, 2021 Filed Nov 10, 2021 18:52 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 287 | $40.61 | $11,655.07 |
DisclosureSEC source: 0001179110-21-010059 · edgar.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 28,026 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on November 6, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
| August 09, 2021 Filed Apr 4, 2022 16:30 UTC | Editas Medicine, Inc. EDIT · Entity 5502 | SaleCommon Stock | 287 | $57.17 | $16,407.79 |
DisclosureSEC source: 0001415889-22-003709 · form4-04042022_040401.xml · nonDerivative · entry 1 Eaton Bruce · CIK 0001874831 · EVP, CHIEF BUSINESS OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,099 F1 · kind: Sale was effected pursuant to a durable automatic sales instruction plan adopted by the Reporting Person on June 15, 2019, and represents the sale of shares by the Issuer necessary to meet tax withholding obligations as a result of vesting in restricted stock units on August 6, 2021. The sale does not represent a discretionary trade by the Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.